Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On July 20, 2022, Mr. Chanan Morris notified the board of directors of Artemis
Therapeutics, Inc. (the "Company") regarding his resignation from his position
as Chief Financial Officer of the Company, effective immediately. Mr. Morris'
resignation was not due to any disagreements with the Company on any matter
relating to the Company's operations, policies or practices.
On July 25, 2022, our Board of Directors appointed Mr. David Dana to act as our
Chief Financial Officer, effective July 26, 2022.
Mr. David Dana, age 58, is a Certified Public Accountant (ISR) and holds an MBA
in Business Administration from Heriot Watt University in the UK. Over the last
12 years Mr. Dana has been the owner of CFO4U, an Israeli company providing
external financial and accounting services to various companies. From 2013 to
2017, Mr. Dana provided financial services to Riskified Ltd (NYSE: RSKD). Mr.
Dana has been providing financial services to Joytunes Ltd. since 2011, to
Powtoon Ltd. and Powtoon Limited since 2013, to Tradair Ltd. since 2013, and to
Substrata Ltd since 2013.
Mr. Dana's monthly compensation will be NIS 10,000 plus VAT. In addition, the
Company will grant Mr. Dana options to purchase 0.33% of the outstanding share
capital of the Company. The exercise price per share shall be calculated based
on the Company's valuation of $7 million. The options will vest over a period of
36 months with one twelfth (1/12) of the options vesting every three months
commencing on April 1, 2022.
Mr. Dana has advised us that he has no arrangement or understanding with any
other person pursuant to which he was appointed as our Chief Financial Officer.
Mr. Dana will be eligible for bonuses and equity grants in amounts to be
determined at the discretion of the Company's Board of Directors. In connection
with Mr. Dana's appointment, the Company expects to enter into its standard
indemnification agreement with Mr. Dana, on substantially the same terms as the
indemnification agreements previously entered between the Company and each of
its directors and executive officers. Mr. Dana is not a party to any
transactions that are disclosable under Item 404 of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
MANUKA, INC. 
